✦ LIBER ✦

Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?

✍ Scribed by Lara Valor; Inmaculada de la Torre Ortega

Book ID: 119358380
Publisher: Elsevier Science
Year: 2012
Tongue: Spanish
Weight: 159 KB
Volume: 8
Category: Article
ISSN: 2173-5743
DOI: 10.1016/j.reumae.2012.06.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Delayed treatment with tumor necrosis fa

Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

✍ Junko Kita; Mami Tamai; Kazuhiko Arima; Yoshikazu Nakashima; Takahisa Suzuki; Sh 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 177 KB

Do rheumatoid arthritis patients have eq

Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries

✍ Joëlle M. Hoebert; Aukje K. Mantel-Teeuwisse; Liset van Dijk; Johannes W.J. Bijl 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Very early treatment with infliximab in

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial

✍ Mark A. Quinn; Philip G. Conaghan; Philip J. O'Connor; Zunaid Karim; Adam Greens 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views